Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Deborah A. Zajchowski"'
Autor:
Donato Tedesco, Jianhuan Zhang, Lan Trinht, Guita Lalehzadeh, Rene Meisner, Ken D. Yamaguchi, Daniel L. Ruderman, Harald Dinter, Deborah A. Zajchowski
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 9, Iss 7, Pp 601-613 (2007)
We identified the ubiquitin-conjugating enzyme E2EPF mRNA as differentially expressed in breast tumors relative to normal tissues and performed studies to elucidate its putative role in cancer. We demonstrated that overexpression of E2-EPF protein co
Externí odkaz:
https://doaj.org/article/9017ae9d1c174fd5bd803faceed9eb13
Autor:
David Kiewlich, Jianhuan Zhang, Cynthia Gross, Wei Xia, Brent Larsen, Ronald R. Cobb, Sandra Biroc, Jian-Ming Gu, Takashi Sato, David R. Light, Tara Heitner, Joerg Willuda, David Vogel, Felipe Monteclaro, Andrzej Citkowicz, Steve R. Roffler, Deborah A. Zajchowski
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 1, Pp 18-30 (2006)
The EphA2 receptor tyrosine kinase has been shown to be over-expressed in cancer and a monoclonal antibody (mAb) that activates and down-modulates EphA2 was reported to inhibit the growth of human breast and lung tumor xenografts in nude mice. Reduct
Externí odkaz:
https://doaj.org/article/8033c22a57da4a11ab4c7b29ceb0609c
Autor:
Edith A. Perez, Ute Hoch, Mary Tagliaferri, Darren W. Davis, Deborah A. Zajchowski, Katie Caygill, Sherwin Sy, Lin Lu, Alison Hannah, Seock-Ah Im, Chris Twelves, Joyce O'Shaughnessy, Ahmad Awada, Javier Cortes, Hope S. Rugo
Supplemental Tables and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aeae1974768278ebba6ac995516949e
https://doi.org/10.1158/1078-0432.22463930.v1
https://doi.org/10.1158/1078-0432.22463930.v1
Autor:
Edith A. Perez, Ute Hoch, Mary Tagliaferri, Darren W. Davis, Deborah A. Zajchowski, Katie Caygill, Sherwin Sy, Lin Lu, Alison Hannah, Seock-Ah Im, Chris Twelves, Joyce O'Shaughnessy, Ahmad Awada, Javier Cortes, Hope S. Rugo
Purpose: Preplanned exploratory analyses were performed to identify biomarkers in circulating tumor cells (CTC) predictive of response to the topoisomerase 1 inhibitor etirinotecan pegol (EP).Experimental Design: The BEACON trial treated patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82620400e04cf4b38c7b5c676547f2b5
https://doi.org/10.1158/1078-0432.c.6525575
https://doi.org/10.1158/1078-0432.c.6525575
Autor:
Luke Juckett, Douglas A. Levine, J. Fehniger, Deborah A. Zajchowski, Julia A. Elvin, Amnon A Berger
Publikováno v:
Gynecologic Oncology. 155:473-482
Objective We analyzed comprehensive genomic sequencing results from paired ovarian cancer samples to identify changes in mutational events over time. Methods DNA from paired FFPE tumor samples from 50 ovarian cancer patients in the Clearity Foundatio
Autor:
Donald P. McDonnell, Fidel A. Valea, Matthew S. Jorgensen, Andrew Berchuck, Ching-Yi Chang, Julia A. Elvin, Meghan Steiner, Deborah A. Zajchowski, Brittany A. Davidson, Kaitlyn Andreano, Laura J. Havrilesky, Angeles Alvarez Secord, Stephanie Gaillard, Gerardo Colon-Otero
Publikováno v:
Gynecologic Oncology. 154:199-206
Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially arom
Autor:
Nikki A. Martin, Janelle Schrag, Cynthia Bens, Claire Saxton, Victor J. Gonzalez, Erica Kuhn, Ronit I. Yarden, Marcia K. Horn, Cassadie Moravek, Gillian W. Hooker, Deborah A. Zajchowski, Christine Verini, Andrea K. Miyahira, Sue Friedman, Reese Garcia, Denisse Montoya, Janine Guglielmino, Beth Davison, Stacie Lindsey
Publikováno v:
Journal of Clinical Oncology. 38:e24164-e24164
e24164 Background: Biomarker testing has advanced precision medicine in cancer. However, not all eligible patients benefit from biomarker-driven therapies due to suboptimal testing rates. A working group of 20 patient advocacy groups representing sol
Autor:
Sherwin K. B. Sy, Deborah D.A. Zajchowski, Ahmad Awada, Javier Cortes, Seock–Ah –A Im, Ute Hoch, Edith A. Perez, Darren W. Davis, Mary Tagliaferri, Lin Lu, Hope S. Rugo, Joyce O'Shaughnessy, Alison L. Hannah, Chris Twelves, Katie Caygill
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(14)
Purpose: Preplanned exploratory analyses were performed to identify biomarkers in circulating tumor cells (CTC) predictive of response to the topoisomerase 1 inhibitor etirinotecan pegol (EP). Experimental Design: The BEACON trial treated patients wi
Autor:
Kai Wang, Doron Lipson, L. K. Shawver, Phillip J. Stephens, Gary A. Palmer, V.A. Miller, Siraj M. Ali, J.S. Ross, Deborah A. Zajchowski, Roman Yelensky
Publikováno v:
Gynecologic Oncology. 130:554-559
Objective Targeted next generation sequencing (NGS) was evaluated for its ability to identify unanticipated targetable genomic alterations (GA) for patients with relapsed ovarian epithelial carcinoma (OC). Methods DNA sequencing was performed for 332
Publikováno v:
Molecular Cancer Therapeutics. 11:492-502
The molecular characteristics of recurrent ovarian cancers following chemotherapy treatment have been poorly characterized. Such knowledge could impact salvage therapy selection. Since 2008, we have profiled 168 patients' ovarian cancers to determine